At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 10, 2026 at 12:03 ET
Teva closed its acquisition of Emalex Biosciences for $700M upfront plus up to $200M in milestones and sales-based royalties, adding ecopipam, a late-stage, first-in-class D1 antagonist for pediatric Tourette syndrome. NDA submission is expected in H2 2026, and Phase 3 data published in JAMA Neurology showed statistical significance on the primary endpoint.
- $700 million upfront consideration paid at closing
- Up to $200 million in additional commercial milestone payments plus net sales-based royalties
- Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations
- Phase 3 Tourette syndrome study met primary endpoint with statistical significance (p = 0.0084) and was published in JAMA Neurology
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access